In order to increase its global footprint and offset declining revenues from its key pain products, acquisitive Endo Health Solutions has agreed to buy Paladin Labs in a mostly stock deal that values the Canadian company at approximately US$1.6 B. As part of a complicated deal structure, the two companies will be acquired by a newly formed Irish holding company in a move to reduce Endo’s corporate tax rate. The acquisition will expand the company’s presence in Canada and provide it with access to emerging markets, including Mexico and South Africa.